Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Free Cash Flow (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Free Cash Flow data on record, last reported at -$14.3 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 173.86% year-over-year to -$14.3 million; the TTM value through Dec 2025 reached $45.0 million, up 151.0%, while the annual FY2025 figure was $45.0 million, 151.0% up from the prior year.
  • Free Cash Flow reached -$14.3 million in Q4 2025 per APLS's latest filing, down from $108.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $108.3 million in Q3 2025 and bottomed at -$177.9 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$85.9 million, with a median of -$112.1 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: crashed 179.65% in 2021, then soared 217.69% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$112.5 million in 2021, then decreased by 25.84% to -$141.6 million in 2022, then surged by 30.81% to -$98.0 million in 2023, then skyrocketed by 119.74% to $19.3 million in 2024, then tumbled by 173.86% to -$14.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$14.3 million in Q4 2025, $108.3 million in Q3 2025, and $4.4 million in Q2 2025.